Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the ...

As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold ...

The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects.

Biogen has emerged as a potential front-runner at the Cannes Lions International Festival of Creativity, snagging four spots ...

One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the ped ...

Biogen begins phase 3 paediatric study of Omaveloxolone to treat Friedreich ataxia: Cambridge, Mass Saturday, June 21, 2025, 11:00 Hrs [IST] Biogen Inc, a leading biotechnology co ...

Biogen Inc. (NASDAQ: BIIB) lost strength in Wednesday trading, after the Cambridge, Mass.-based company announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The ...

The winning work from Ogilvy Shanghai answered the question of how to promote Viagra in a country where pharma ads are banned ...

Since McKinney Health burst onto the scene in 2022, it has been carving out its place at the intersection of health and life.

Biogen paid Sage $11 million in collaboration revenues in the third quarter, during which the drug made $22 million, and buying Sage would give it total control of the brand. At last week's ...